Phase 1/2 Trial to Evaluate the Safety and Efficacy of PEEL-224 in Combination With Vincristine and Temozolomide in Adolescents and Young Adults With Relapsed or Refractory Sarcomas

Clinical trial NCT06709495 · RECRUITING

Trial details

NCT number: NCT06709495
Sponsor: David S Shulman, MD
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Sarcoma Sarcoma, Ewing Desmoplastic Small Round Cell Tumor Refractory Sarcoma Osteosarcoma Rhabdomyosarcoma

Start date: 2025-01-27
Primary completion: 2028-11-01
Enrollment: 63

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.